about
Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyPrimary Retroperitoneal Cystoadenocarcinoma: A Systematic Review.The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.Systemic adjuvant therapies in renal cell carcinomaBenefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.Lymph node ratio improves TNM and Astler-Coller's assessment of colorectal cancer prognosis: an analysis of 761 node positive cases.Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma.Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer."Finding NEMO" in NRAS-mutant melanoma: a step towards a sequential strategy?Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinomaClinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumabSpotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to dateAtezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell CarcinomaLoss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumabINfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa studyPathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptionsA multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableCombination therapy in kidney cancer: the next revolution?Non-clear-cell renal carcinoma therapy: handle with careFamily history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study
P50
Q28079861-A1EF248B-A39C-4B2D-8B60-407D5147AA7FQ30249573-55491E0C-8B0C-4974-B9C6-2BD0020BBEDAQ30250343-562FC7CA-2DEE-495B-B9A7-6AD4E05F502BQ34774866-87F3E874-2E85-46AA-BE02-23E44D9563F9Q35569322-5D93A87F-5240-40F2-A1CF-696F9206EED5Q36291489-8BFD195A-EE17-464D-AF3C-8D80E672A7A4Q37642460-5A8E555A-89B0-42A0-B4A1-313AB733F2CFQ37952236-5375231D-2C8F-470C-A48B-BEF662855E17Q38685048-2C298CD1-A59E-409B-BBD1-07D08FF588F6Q38693856-79090324-1D9B-4872-A134-C7E922CB6400Q38742992-FEF7C39A-5567-4CBD-8E0D-B016B3488850Q39009124-F33DC4DA-5221-4C5F-9B7B-1302FB22D578Q39148839-F4791F5D-A83F-47B3-ADB6-1F1DAC5EB826Q39442851-499E82E2-05FF-46E8-A46D-E9B65CEC5C37Q40429650-8CF38D66-4368-4046-B060-94F51926FAD4Q41624982-9AAEAAE8-154F-44E1-A86B-2B0E7462F338Q42257155-CC5B2C4C-E3AD-4E1F-B8E0-ED7BC1341BB7Q42696368-83B50530-E918-48FF-AB40-6EB411EBBBDFQ46060710-87E4226E-9D1B-470D-820F-A016AB16C2F2Q47151381-190C7E55-288D-4B53-B01E-6D14AFE5F16AQ47261072-7361DB4F-4024-47F0-83CB-492329FB4A8FQ47874565-62F1972F-B630-4A17-8ED9-C495EB4BE842Q48085625-1362835B-65E2-43C9-9F6D-EA304305DED7Q48771536-01294980-142D-44AC-AFD7-30661A464156Q54167321-2EF54253-4685-42CC-B69A-D92F74EE7B0CQ54173921-FD9983F1-8D74-4A4A-B819-5B66EBD69249Q55068923-3DD4A816-7111-42E7-BE86-4A3AF19E92CBQ55312003-882835A1-B1EE-480A-9165-27EA6A6F8E1DQ56351538-6AB4AEC2-B4AE-4B86-AE31-1E9D7EC2B71EQ56380345-D953C7A1-F1E7-4573-BB6C-F87CE7D1583FQ57071032-9561288A-A588-4407-A7BC-A8808068C387Q58128608-A56E8261-D846-4134-BE5B-178B9EDA77C2Q61447437-D5354ACE-795C-42DB-AB46-9921783F2133Q61982319-36EA632D-F320-43B5-8F64-10DBA5571839Q62661806-E304C43D-FEE3-4B81-B44B-B3A71A6D420AQ64073953-71FADA67-2269-42AF-A9A9-161845BC916AQ64095960-0583AB37-5E8F-47A0-AAC6-C4DFA568B0D2Q86515843-37C3166D-F2D6-451F-9462-70123815711FQ87449816-7E95F230-1336-40BF-B377-69658CD9B327Q88122246-EE4C8691-6D9B-403D-BAF7-0CCEA41B5B67
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Melissa Bersanelli
@ast
Melissa Bersanelli
@en
Melissa Bersanelli
@es
Melissa Bersanelli
@nl
type
label
Melissa Bersanelli
@ast
Melissa Bersanelli
@en
Melissa Bersanelli
@es
Melissa Bersanelli
@nl
prefLabel
Melissa Bersanelli
@ast
Melissa Bersanelli
@en
Melissa Bersanelli
@es
Melissa Bersanelli
@nl
P106
P1153
49963037300
P31
P496
0000-0002-6527-6281